Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Selinexor and Venetoclax Combination in Patients With Relapsed or Refractory Acute Myeloid Leukemia.
Selinexor and Venetoclax Combination in Patients With Relapsed or Refractory Acute Myeloid Leukemia.
Journal: American journal of hematology
Published: January 05, 2026
American Society of Hematology 2026 guidelines for the diagnosis and management of severe and very severe acquired aplastic anemia.
Journal: Blood advances
Published: November 10, 2025
Who Is Eligible for Chimeric Antigen Receptor T Cell Therapy? Expert Perspectives on Overcoming Referral Barriers.
Journal: Transplantation and cellular therapy
Published: July 03, 2025
Key Challenges in CAR T-Cell Therapy Access in Community Oncology.
Journal: JAMA oncology
Published: March 06, 2025
Eprenetapopt Plus Azacitidine After Allogeneic Hematopoietic Stem-Cell Transplantation for TP53-Mutant Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 11, 2022
Feasibility of outpatient administration of axicabtagene ciloleucel and brexucabtagene autoleucel using telemedicine tools: The Vanderbilt experience.
Journal: British journal of haematology
Published: May 18, 2022
New-onset post-transplant diabetes mellitus after haploidentical hematopoietic cell transplant with post-transplant cyclophosphamide.
Journal: EJHaem
Published: March 12, 2021
Machine learning reveals chronic graft-versus-host disease phenotypes and stratifies survival after stem cell transplant for hematologic malignancies.
Journal: Haematologica
Published: March 17, 2018
Outcomes of a novel rituximab-based non-myeloablative conditioning regimen for hematopoietic cell transplantation in severe aplastic anemia.
Journal: Bone marrow transplantation
Published: October 12, 2017
Last Updated: 09/26/2026